Acetyldihydrocodeine Stats & Data

• Prodrug pathway: 6-acetyl ester rapidly deacetylates to dihydrocodeine, which is O-demethylated by CYP2D6 to the higher-affinity agonist dihydromorphine; CYP2D6 poor metabolisers may feel little effect, while ultrarapid metabolisers face stronger-than-expected effects at standard doses. • The intrinsic serotonergic activity of dihydrocodeine/dihydromorphine is minimal; serotonin syndrome is uncommon unless combined with MAOIs or strongly serotonergic drugs—caution still warranted, particularly in ultrarapid CYP2D6 metabolisers. • Polydrug risk: combining with other CNS depressants (alcohol, benzodiazepines, gabapentinoids, Z-drugs, barbiturates, GHB) markedly increases respiratory depression and overdose risk; avoid these combinations and never use alone. • If using pharmaceutical combination products, check for acetaminophen/paracetamol; keep total APAP ≤3–4 g/day and consider a cold-water extraction (CWE) if necessary to avoid hepatotoxicity. • Consider fentanyl test strips when using non-medical powders/tablets—fentanyl analog contamination has been widely reported in opioid markets; use a small, well-mixed sample for testing. • Keep naloxone on hand; teach peers to recognise overdose (unresponsiveness, slow/absent breathing, cyanosis, pinpoint pupils) and to give rescue breaths while awaiting help; naloxone may require repeat dosing due to shorter half-life than many opioids. • Insufflation damages nasal mucosa and may be inefficient for a prodrug; oral or rectal routes are generally safer and more predictable. If snorting, use clean, personal tools and rinse with saline. • Rectal use: use only clean water, small volumes, and gentle insertion; avoid irritants/solvents; retain for several minutes to absorb. • Avoid redosing within the first 90 minutes due to delayed prodrug conversion; stacking doses increases risk of delayed respiratory depression. • Opioid constipation is common—hydrate, increase fiber, and consider a stool softener or osmotic laxative (e.g., PEG). • Increased histamine release may cause itch and flushing; non-sedating antihistamines (e.g., cetirizine) are preferable to sedating ones that add respiratory/CNS depression. • Elevated risk groups: respiratory disease (COPD, OSA), hepatic impairment (slower metabolism), renal impairment (metabolite accumulation), pregnancy (neonatal withdrawal), and breastfeeding (CYP2D6 ultrarapid metaboliser mothers linked to infant toxicity on codeine-like prodrugs). • Store cool and dry; moisture can promote hydrolysis to dihydrocodeine, altering potency over time. • Never inject: acetyldihydrocodeine is poorly water-soluble; insoluble fillers and esters present high risks of embolism, infection, and overdose. • Standard opioid immunoassays typically detect related metabolites; expect positive “opiates” screens.